熱門資訊> 正文
美国银行在购买时启动透视，引用放射性铅-212的使用
2024-07-26 03:44
- BofA has started coverage of Perspective Therapeutics (NYSE:CATX) with a buy rating, citing the company’s unique approach to radiopharmaceuticals by using radioactive Lead-212, or 212pb.
- The investment bank said using 212pb allowed the company to circumvent the current shortages of other common radioisotopes. 212pb also has a shorter half-life and carries lower off-target toxicity risk with improved decay chain than Actinium-225, it added.
- BofA said Perspective (CATX) currently has around $250M to $300M in cash, which should be able to fund operations into mid-2026, “well beyond near-term points for value inflection." It added that upcoming Phase 1 data for its lead programs will be key catalysts in the second half of the year and serve to further de-risk its approach.
- The investment bank set its price objective for the stock at $24.
More on Perspective Therapeutics
- Perspective Therapeutics: An Elevated Theranostics Play Flying Under Your Radar
- Seeking Alpha’s Quant Rating on Perspective Therapeutics
- Historical earnings data for Perspective Therapeutics
- Financial information for Perspective Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
